Interferon-β (IFN-β) is a cytokine that belongs to type I interferons. The IFN-β gene is mapped on the human chromosome at 9p21.3.
Immunogen
a 17 amino acid peptide from near the center of human IFN-b.
Biochem./physiol. Wirkung
Interferon-β (IFN-β) plays a major role in antibacterial and antiviral defense. It is also involved in apoptosis, cell growth, and autoimmune disorders. It binds to multimeric cell receptors and successful binding results in a cascade of intracellular events.
Verlinkung
The action of this antibody can be blocked using blocking peptide SBP4243.
Physikalische Form
Solution in phosphate buffered saline containing 0.02% sodium azide
Haftungsausschluss
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Journal of immunology (Baltimore, Md. : 1950), 198(10), 4036-4045 (2017-04-16)
Type I IFNs are a cytokine family essential for antiviral defense. More recently, type I IFNs were shown to be important during bacterial infections. In this article, we show that, in addition to known cytokine functions, IFN-β is antimicrobial. Parts
Repetitive implant-related infections (IRIs) are devastating complications in orthopedic surgery, threatening implant survival and even the life of the host. Biofilms conceal bacterial-associated antigens (BAAs) and result in a "cold tumor"-like immune silent microenvironment, allowing the persistence of IRIs. To
Clinical pharmacology and therapeutics, 78(6), 635-646 (2005-12-13)
Interferon IFN-beta is indicated for the treatment of multiple sclerosis. A significant proportion of patients show a poor clinical response to therapy. Type I interferon exerts its effect at least partially through interaction of specific transcription factors with interferon-stimulated response
Two recombinant IFN-beta products have been approved for the treatment of multiple sclerosis, a glycosylated form with the predicted natural amino acid sequence (IFN-beta-1a) and a non-glycosylated form that has a Met-1 deletion and a Cys-17 to Ser mutation (IFN-beta-1b).
Fragen
Bewertungen
★★★★★ Kein Beurteilungswert
Aktive Filter
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
